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To the Editor: 20 
Two recent publications in this Journal provided interesting reading regarding the metabolomics of 21 
asthma. Fitzpatrick et al. (1) and Loureiro et al. (2) identified metabolites and metabolic pathways 22 
suggesting that oxidative stress is a factor contributing to asthma severity in children and asthma 23 
exacerbation in adults, respectively. Although these findings support a role for oxidative stress in 24 
asthma, these studies have some limitations. 25 
It is not clear, due to the design of the studies, whether the reported and highlighted metabolites are a 26 
proxy for oxidative stress contributing to severe asthma and asthma exacerbation or a consequence of 27 
the disease. It is also not completely clear if the findings are driven by use of medication – this is 28 
common to both studies, but particularly relevant in the study by Loureiro et al. since samples from 29 
the exacerbation period were collected after the treatment provided at the emergency room. The two 30 
groups of children from the study by Fitzpatrick et al. are not totally comparable, since the group with 31 
severe asthma was almost exclusively non-white, unlike the control group (mild asthma), and racial 32 
differences in biological predictors of severe asthma have been previously reported (3). In addition, 33 
the use of non-fasting samples raises the question whether the results might have been influenced by 34 
diet, since several food items have been shown to associate with specific metabolites (4), and the 35 
short-term effects of diet on the metabolome is uncertain. Finally, like most of the previous studies on 36 
metabolomics of asthma (table 1), these were pilot studies (small by nature) that could not adjust for 37 
potential confounders.  38 
Fitzpatrick et al. and Loureiro et al., together with previous studies, have shown several metabolites 39 
and pointed out several pathways that could characterize asthma or asthma exacerbation. Not all 40 
studies used the same methods (some used NMR, others MS) or sample types (some used serum, 41 
others urine or exhaled breath condensate) nor collected fasting samples nor controlled for the use of 42 
asthma- and non-asthma-related drugs or comorbidities. This should remind us of what we have seen 43 
when large genome-wide association studies failed to replicate tens of SNPs that were previously 44 
found associated with disease in small candidate gene studies. Nevertheless, the present findings, as 45 
those from previous studies, are excellent candidate metabolites to be replicated in future and larger 46 
studies. 47 
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In summary, on the basis of the publications by Fitzpatrick et al. and Loureiro et al., some may 48 
conclude that we have enough information to move to the development of treatments targeting the 49 
oxidative stress-related pathways. Unfortunately, we are still far from understanding the real meaning 50 
of these metabolites, and we cannot exclude that some of current findings might be false positives that 51 
will not be replicated in larger and better controlled studies. Randomized trials and animal model 52 
studies showing the effects of controller drugs on the metabolic profile should provide important 53 
information that will help to disentangle the effect of such drugs on the metabolome. 54 
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Table 1. Summary of previous publications on metabolomics of asthma and their main findings and issues. 
First author 
[year] 
Study population  Type of 
sample  
Analytical 
method  
Main findings Main issues  
Children      
Carraro 
[2007] E1 
- 25 asthmatics (17 persistent asthma 
treated with ICS; 8 intermittent asthma 
with no ICS in previous month) 
- 11 healthy age-matched controls 
Exhaled 
breath 
condensate  
NMR - Acetylated products (1.7-2.2 ppm spectral region) and 
oxidized compounds (3.2-3.4 ppm spectral region) 
discriminated asthmatics from non-asthmatics  
- Small sample size 
- Not clear what 
metabolites have 
been identified 
- Role of ICS in the 
findings not clear  
Saude 
[2011] E2 
- 73 with stable atopic asthma, 67% with 
ICS 
- 20 with unstable asthma in emergency 
room; 50% with ICS 
- 42 healthy age- and sex-matched (10 
confirmed non-atopic) 
Urine  NMR  - Several metabolites, from several pathways, 
discriminated asthma exacerbation from stable asthma 
- Small sample size 
- Role of ICS in the 
findings not clear 
- Treatment given at 
emergency not 
mentioned 
Mattarucchi 
[2012] E3 
- 41 atopic asthmatics (14 with SABA; 
16 with low conc. ICS + LABA; 11 
with high conc. ICS + LABA) 
- 12 age-matched non-atopic non-
asthmatics 
Urine  LC-MS  - Low levels of urocanic acid, methyl-
imidazoleacetic acid, and a metabolite like isoleucyl-
proline in asthmatics 
- Small sample size 
- Role of ICS in the 
findings not clear  
Sinha 
[2012] E4 
- 58 asthmatics 
- 2 healthy, non-asthmatics  
Exhaled 
breath 
condensate  
NMR  - Asthmatics showed lack of ammonium ions - Small sample size 
- No mention on the 
use of ICS or any 
other treatment  
Carraro 
[2013] E5 
- 42 atopic asthmatics [31 with non-
severe asthma (17 with low-medium 
conc. ICS alone or combined with 
LABA mainly; 14 ICS naive); 11 with 
severe asthma with high conc. ICS (and 
others) + LABA 
- 15 healthy 
Exhaled 
breath 
condensate 
NMR  - High levels of retinoic acid- and deoxyadenosine-
related metabolites in severe asthmatics 
- Low levels of ercalcitriol in severe asthmatics 
- Low levels of 20-hydroxy-PGF2a, 6-keto-
prostaglandin F1a, and thromboxane B2 in severe 
asthmatics  
- Small sample size  
- Role of ICS in the 
findings not clear 
Gahleitner 
[2013] E6 
- 25 asthmatics (17 persistent asthma 
treated with ICS; 8 intermittent asthma 
with no ICS in previous month) 
- 11 healthy age-matched controls 
Exhaled 
breath 
condensate 
(fasting)  
 GC-MS  - Eight metabolites discriminated asthmatics from 
healthy children: 1-
(methylsulfanyl)propane, ethylbenzene, 1,4-
dichlorobenzene, 4-isopropenyl-1-methylcyclohexene, 
- Small sample size  
- Role of ICS in the 
findings not clear  
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2-octenal, octadecyne, 1-isopropyl-3-methylbenzene, 
and 1,7-dimethylnaphtalene  
Adults      
Sinha 
[2012] E4 
- 7 asthmatics (non-smokers) 
- 10 healthy non-asthmatics (non-
smokers) 
Exhaled 
breath 
condensate  
NMR  - Lack of ammonium ions in asthmatics - Small sample size 
- No mention on the 
use of ICS or any 
other treatment  
Ibrahim 
[2013] E7 
- 79 asthmatics (77% with ICS)  
- 34 controls 
Exhaled 
breath 
condensate 
NMR - Five spectral regions distinguished asthmatics from 
controls (AUC = 0.91)  
- Small sample size  
- Role of ICS in 
findings not clear 
- Controls were about 
14 years younger 
than asthmatics  
Jung 
[2013] E8 
- 39 asthmatics (77% with ICS - they 
stopped their medication for at least 3 
days before sample collection;  44% 
were atopic) 
- 26 healthy controls 
Serum  NMR  - High levels of methionine, glutamine, histidine, and 
lower levels of formate, methanol, acetate, choline, O-
phosphocholine, arginine, and glucose in asthmatics 
- Small sample size  
- Medication stopped 
3 days before 
sample collection, 
but ICS-related 
DNA methylation 
effect should not be 
excluded  
Loureiro 
[2013] E9 
- Woman with severe persistent allergic 
asthma treated with omalizumab 
Urine GC-MS  - Previous to treatment, main metabolites were alkanes. 
12 weeks after, aldehydes were the main metabolites  
- Just one case  
Ried 
[2013] E10 
- 260 asthmatics from the KORA cohort 
(asthmatics with three definitions: 260 
ever asthmatics; 147 non-medicated 
current asthmatics; 104 medicated 
asthmatics) 
- 2,778 never asthmatics (controls)  
 Serum 
(fasting)  
ESI-
MS/MS 
- High levels of phosphatidylcholines and low levels 
of lyso-phosphatidylcholines in current asthmatics 
(similar results for medicated asthma)  
- Changes in levels of 
polyunsaturated phosphatidylcholines were associated 
with asthma and affected by asthma risk alleles 
(in PSMD3 and MED24)  
- Causality could not 
be established  
ESI-MS/MS = Electrospray ionization tandem mass spectrometry; ICS = inhaled corticosteroids; LC-MS = liquid chromatography mass spectrometry; GC-MS = gas 
chromatography mass spectrometry; NMR = nuclear magnetic resonance; SABA = short-acting beta agonists; LABA = long-acting beta agonist. 
For full list of citations (E1 to E10) in this table please see this article’s Online Repository available at www.jacionline.org. 
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